Latest News and Press Releases

New York, USA, June 18, 2026 (GLOBE NEWSWIRE) -- Global Cell and Gene Therapy CDMO Market Anticipating Remarkable Growth at a CAGR of ~24% by 2034 | DelveInsight The cell and gene therapy CDMO...

DYADIC ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS

If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European UnionItvisma...

Ottawa, April 20, 2026 (GLOBE NEWSWIRE) -- Precedence Research, a leading provider of market intelligence and healthcare analytics solutions, today announced the launch of its Cell and Gene Therapy...

A year of strategic execution, strong revenue growth and positive Operating EBITDA Strong 2025 financial performance; revenues at upper end of guidance, with full year Operating EBITDA profitability...

Corporate AI investment across all sectors totaled $252.3 billion in 2024, with mergers and acquisitions up 12.1% and private investment rising 44.5%.

The Cell & Gene Therapy CDMO market is growing with rising CGT pipelines, outsourcing, and viral vector demand.

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

OXB announces date for Capital Markets Day and participation in upcoming investor conferences Oxford, UK – 3 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy...

Ottawa, Jan. 29, 2026 (GLOBE NEWSWIRE) -- The global cell and gene therapy manufacturing market size was calculated at USD 21.15 billion in 2025 and is expected to reach around USD 215.18 billion by...